Bespak

Executive Summary

Bespak is a UK-based CDMO with over 50 years of expertise in inhaled and nasal drug delivery. The company offers end-to-end services from early development through regulatory approval to commercial supply for pMDIs, DPIs, soft mist inhalers, and nasal devices. As a private firm with a strong reputation in a niche but growing market, Bespak benefits from increasing demand for respiratory therapies and the trend toward drug-device combination products. Its long-standing relationships with top pharma companies and technical know-how in device design and manufacturing position it as a preferred partner for complex inhalation products. The company's growth is driven by the rising prevalence of respiratory diseases and the shift toward specialized CDMO partnerships. Bespak's ability to navigate stringent regulatory requirements and provide innovative device solutions gives it a competitive edge. With a focus on expanding its capacity and capabilities, Bespak is well-positioned to capture a larger share of the respiratory CDMO market. However, as a private entity, financial transparency is limited, and its performance is closely tied to the success of its clients' pipeline products. Overall, Bespak remains a key player in the inhalation drug delivery space, with opportunities linked to new product launches and capacity expansions.

Upcoming Catalysts (preview)

• Q3 2026Securing a Major Commercial Contract for a Late-Stage Inhaler Product70% success
• Q4 2026Announcement of Manufacturing Capacity Expansion in King's Lynn60% success
• TBDStrategic Partnership for Next-Generation Nasal Delivery Platform50% success